421 related articles for article (PubMed ID: 20215534)
21. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
22. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.
Eiblmaier M; Meyer LA; Watson MA; Fracasso PM; Pike LJ; Anderson CJ
J Nucl Med; 2008 Sep; 49(9):1472-9. PubMed ID: 18703609
[TBL] [Abstract][Full Text] [Related]
23. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy.
Bryan JN; Jia F; Mohsin H; Sivaguru G; Anderson CJ; Miller WH; Henry CJ; Lewis MR
Cancer Biol Ther; 2011 Jun; 11(12):1001-7. PubMed ID: 21464612
[TBL] [Abstract][Full Text] [Related]
25. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K
Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621
[TBL] [Abstract][Full Text] [Related]
26. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
27. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
28. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
Atkinson DM; Clarke MJ; Mladek AC; Carlson BL; Trump DP; Jacobson MS; Kemp BJ; Lowe VJ; Sarkaria JN
Head Neck; 2008 Jun; 30(6):790-9. PubMed ID: 18286491
[TBL] [Abstract][Full Text] [Related]
29. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies.
Barnea I; Haif S; Keshet R; Karaush V; Lev-Ari S; Khafif A; Shtabsky A; Yarden Y; Vexler A; Ben Yosef R
Head Neck; 2013 Mar; 35(3):399-407. PubMed ID: 22367849
[TBL] [Abstract][Full Text] [Related]
30. Silencing heat shock protein 27 decreases metastatic behavior of human head and neck squamous cell cancer cells in vitro.
Zhu Z; Xu X; Yu Y; Graham M; Prince ME; Carey TE; Sun D
Mol Pharm; 2010 Aug; 7(4):1283-90. PubMed ID: 20540527
[TBL] [Abstract][Full Text] [Related]
31. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
32. Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts.
Li W; Zheng H; Xu J; Cao S; Xu X; Xiao P
PLoS One; 2018; 13(6):e0199024. PubMed ID: 29894497
[TBL] [Abstract][Full Text] [Related]
33. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
[TBL] [Abstract][Full Text] [Related]
34. Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice.
Zeng D; Guo Y; White AG; Cai Z; Modi J; Ferdani R; Anderson CJ
Mol Pharm; 2014 Nov; 11(11):3980-7. PubMed ID: 24720806
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
36. Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma.
Braakhuis BJ; Jansen G; Noordhuis P; Kegel A; Peters GJ
Biochem Pharmacol; 1993 Dec; 46(12):2155-61. PubMed ID: 7506025
[TBL] [Abstract][Full Text] [Related]
37. Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.
Song IH; Noh Y; Kwon J; Jung JH; Lee BC; Kim KI; Lee YJ; Kang JH; Rhee CS; Lee CH; Lee TS; Choi IJ
Oncotarget; 2017 Nov; 8(54):92090-92105. PubMed ID: 29190900
[TBL] [Abstract][Full Text] [Related]
38. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution, pharmacokinetics and radioimmunotherapy of
Chang YJ; Ho CL; Cheng KH; Kuo WI; Lee WC; Lan KL; Chang CH
Invest New Drugs; 2019 Oct; 37(5):961-972. PubMed ID: 30612308
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines.
Peng W; de Bruijn HS; Farrell E; Sioud M; Mashayekhi V; Oliveira S; van Dam GM; Roodenburg JLN; Witjes MJH; Robinson DJ
Lasers Surg Med; 2018 Jul; 50(5):513-522. PubMed ID: 29777587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
